Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy

Immunosuppressive cytokines have the potential to promote prostate cancer progression. Assessing their longitudinal changes may implicate mechanisms of progression, treatment resistance, and suggest new therapeutic targets.

[1]  C. Drake,et al.  A role for paracrine interleukin‐6 signaling in the tumor microenvironment in prostate tumor growth , 2018, The Prostate.

[2]  R. Ummanni,et al.  Interleukin‐6 induced overexpression of valosin‐containing protein (VCP)/p97 is associated with androgen‐independent prostate cancer (AIPC) progression , 2018, Journal of cellular physiology.

[3]  K. Iguchi,et al.  Interleukin‐6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation , 2018, The Prostate.

[4]  S. Barry,et al.  IL-23 secreted by myeloid cells drives castration-resistant prostate cancer , 2018, Nature.

[5]  A. Pandiella,et al.  Neutrophils in cancer: prognostic role and therapeutic strategies , 2017, Molecular Cancer.

[6]  C. Drake,et al.  Myeloid‐derived cells in prostate cancer progression: phenotype and prospective therapies , 2017, Journal of leukocyte biology.

[7]  R. Halaban,et al.  Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  I. Thompson,et al.  A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[9]  B. Fraile,et al.  Expression of several cytokines in prostate cancer: Correlation with clinical variables of patients. Relationship with biochemical progression of the malignance , 2017, Cytokine.

[10]  Yi Xiao,et al.  Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer , 2016, Medicine.

[11]  R. Vessella,et al.  A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells , 2015, Cancer Immunology Research.

[12]  M. Stockler,et al.  Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer , 2015, British Journal of Cancer.

[13]  W. Isaacs,et al.  A Peripheral Circulating TH1 Cytokine Profile Is Inversely Associated with Prostate Cancer Risk in CLUE II , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[14]  J. Kliment,et al.  Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. , 2014, European urology.

[15]  Jennifer R. Rider,et al.  Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and overall survival , 2014, The Prostate.

[16]  Ben Tran,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[17]  Yezi Zhu,et al.  Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells , 2014, The Prostate.

[18]  Donna L Berry,et al.  Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.

[19]  E. Antonarakis,et al.  Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. , 2013, Clinical advances in hematology & oncology : H&O.

[20]  Fred Saad,et al.  Intermittent androgen suppression for rising PSA level after radiotherapy. , 2012, The New England journal of medicine.

[21]  C. Drake,et al.  Lenalidomide modulates IL‐8 and anti‐prostate antibody levels in men with biochemically recurrent prostate cancer , 2012, The Prostate.

[22]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[23]  S. Steinberg,et al.  A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. , 2009, The Journal of urology.

[24]  A. D'Amico,et al.  Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy , 2009, Cancer.

[25]  D. Fox,et al.  Th17 cells in human disease , 2008, Immunological reviews.

[26]  S. Araki,et al.  Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. , 2007, Cancer research.

[27]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[28]  C. Reddy,et al.  Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. , 2006, Urology.

[29]  C. Tangen,et al.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Hurt,et al.  The role of IL-6 and STAT3 in inflammation and cancer. , 2005, European journal of cancer.

[31]  R. Stock,et al.  Serum Interleukin-8 is Elevated in Men with Prostate Cancer and Bone Metastases , 2004, Technology in cancer research & treatment.

[32]  K. Syrigos,et al.  Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer , 2004, British Journal of Cancer.

[33]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[34]  Sang Eun Lee,et al.  Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. , 2002, The Journal of urology.